Table of Contents
The World's Most Common Mental Disorder
Anxiety disorders affect 284 million people worldwide, making them the most prevalent mental disorders globally (WHO, 2017). Brazil has the highest prevalence of anxiety disorders of any country — 9.3% of the population. The COVID-19 pandemic worsened this picture: it is estimated to have increased the global prevalence of anxiety and depression by 25%.
1. Epidemiology & Impact
Anxiety disorders are the most common category of mental disorders across all age groups. They are not merely "nervousness" or "weakness" — they are neurobiological conditions with genetic basis, altered brain circuits, and measurable physiological responses.
Anxiety has an enormous economic cost: patients with anxiety disorders use healthcare services 3–5 times more than the general population, frequently treated for somatic complaints (chest pain, dizziness, GI dysfunction) before receiving the correct psychiatric diagnosis. On average, the correct diagnosis takes 9 to 12 years from symptom onset.
2. Neurobiology of Fear and Anxiety
Pathological anxiety results from hyperactivation of the fear response system, involving specific brain structures:
- Amygdala — fear processing center; hyperactive in anxiety disorders. Detects threats and triggers fight-or-flight response via the hypothalamus.
- Prefrontal cortex (PFC) — responsible for regulating the amygdala (fear extinction); functionally reduced in anxiety disorders.
- Hippocampus — contextualizes fear memories; dysfunction contributes to fear generalization (generalized anxiety).
- Locus coeruleus — primary source of norepinephrine; hyperactivity produces physical anxiety symptoms (tachycardia, tremors, sweating).
- HPA axis — chronic cortisol reduces hippocampal volume and worsens emotional regulation.
Key neurotransmitters: GABA (main inhibitory — reduced in anxiety), glutamate (excitatory — increased), serotonin (mood and fear modulation — reduced), norepinephrine (arousal and stress response — increased).
3. Types of Anxiety Disorders (DSM-5)
| Disorder | Core Feature | Lifetime Prevalence |
|---|---|---|
| Generalized Anxiety Disorder (GAD) | Excessive, uncontrollable worry about multiple topics for ≥ 6 months | 5–9% |
| Panic Disorder (PD) | Recurrent unexpected panic attacks + anticipatory anxiety | 3–5% |
| Social Anxiety Disorder (SAD) | Intense fear of social/performance situations; social avoidance | 12–13% |
| Specific Phobias | Irrational intense fear of specific object/situation (heights, needles, etc.) | 7–9% |
| Separation Anxiety Disorder | Excessive anxiety about separation from attachment figures (not only children) | 4–5% |
| Agoraphobia | Fear of places difficult to escape (public transport, open spaces, crowds) | 1.7% |
The Panic Attack — What Happens in the Body
A panic attack is a sudden episode of intense fear peaking within minutes, with physical symptoms mimicking a myocardial infarction or stroke — leading many patients to the emergency room repeatedly before the correct diagnosis. Symptoms include: tachycardia, chest pain, shortness of breath, paresthesias, dizziness, sweating, tremors, sense of impending doom or of "going crazy."
Biologically, a panic attack is a massive activation of the sympathetic nervous system — a fight-or-flight response triggered erroneously, without a real threat present.
DSM-5 Diagnostic Criteria for GAD
- Excessive anxiety and worry about a number of events or activities, occurring more days than not for at least 6 months.
- Difficulty controlling the worry.
- Three or more: restlessness/feeling keyed up, easily fatigued, difficulty concentrating, irritability, muscle tension, sleep disturbance.
- The anxiety causes clinically significant distress or impairment in social, occupational, or other functioning.
- Not attributable to substances or another medical condition.
5. Cognitive Behavioral Therapy (CBT): The Gold Standard
CBT has the highest level of evidence of any psychological treatment for all anxiety disorders — comparable in efficacy to medication for GAD, and superior to medication for panic disorder and social anxiety in long-term studies.
CBT therapeutic mechanisms include:
- Cognitive restructuring — identifying and challenging catastrophic automatic thoughts ("what if something terrible happens?"). The therapist helps the patient evaluate the actual probability of feared catastrophes.
- Graduated exposure — progressive exposure to feared stimuli, in imagination or in vivo, without avoidance. Produces fear extinction via prefrontal cortex inhibition of the amygdala.
- Relaxation techniques — diaphragmatic breathing, progressive muscle relaxation (Jacobson). Reduce autonomic arousal.
- Psychoeducation about anxiety — understanding that physical symptoms are harmless reduces fear of fear (agoraphobia, health anxiety).
6. Pharmacotherapy: SSRIs, SNRIs & Others
| Medication | Class | Main Indications | Notes |
|---|---|---|---|
| Escitalopram / Sertraline | SSRI | GAD, panic, social anxiety, OCD | 1st line; onset 2–6 weeks; possible initial worsening |
| Venlafaxine / Duloxetine | SNRI | GAD, panic, social anxiety | Also useful in comorbid chronic pain; caution in hypertension |
| Buspirone | Azapirone (5-HT1A partial agonist) | GAD (especially) | No dependence; slow onset (2–4 weeks); doesn't work for panic |
| Pregabalin | Anticonvulsant (α2δ ligand) | GAD | Fast action (1 week); risk of sedation and mild dependence |
| Benzodiazepines (alprazolam, clonazepam) | GABA-A modulator | Acute anxiety / therapeutic bridges | NOT recommended for chronic treatment — dependence, sedation risk |
| Propranolol | Beta-blocker | Performance anxiety | Reduces physical symptoms (tachycardia, tremor) before specific events |
Benzodiazepines are frequently prescribed for chronic anxiety, but international guidelines contraindicate use beyond 2–4 weeks outside specific contexts, due to risk of physical dependence, sedation, cognitive impairment (especially in the elderly), and paradoxical long-term anxiety maintenance.
7. Complementary Evidence-Based Strategies
- Aerobic exercise — a 2019 meta-analysis (Stubbs et al.) showed significant reduction in anxiety symptoms. Mechanisms include increased BDNF, HPA axis regulation, and hippocampal neuroplasticity. Goal: 30–45 min of moderate exercise, 3–5 times/week.
- Mindfulness-Based Stress Reduction (MBSR) — demonstrated a 38% reduction in GAD symptoms in an RCT (Hoge et al., JAMA Psychiatry 2023).
- Caffeine restriction — caffeine above 400 mg/day precipitates anxiety and panic in sensitive individuals (adenosine antagonism → noradrenergic activation).
- Sleep hygiene — sleep deprivation increases amygdala reactivity to negative stimuli by up to 60% (Walker et al.). Treating insomnia is an essential part of anxiety management.
- Alcohol reduction — although alcohol acutely relieves anxiety (GABAergic effect), it worsens anxiety chronically via noradrenergic rebound and sleep disruption.
8. When to Seek Professional Help
Adaptive anxiety (response to real stressors) is normal and necessary. It becomes a clinical problem when:
- Worry is excessive, uncontrollable and disproportionate to the event
- Lasting more than 6 months (GAD criterion)
- Causing significant subjective distress
- Impairing professional, social or family functioning
- Associated with avoidance of normal life situations
- Not responding to self-care strategies after a few weeks
Anxiety disorders have a 70–80% positive response rate to combined treatment (CBT + medication when indicated). Seeking help from a psychiatrist or CBT-specialized psychologist is the most efficient path to recovery.
References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. (DSM-5). Washington, DC: APA, 2013.
2. Bandelow B, et al. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93-107.
3. Hofmann SG, et al. The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. Cognit Ther Res. 2012;36(5):427-440.
4. Hoge EA, et al. Mindfulness-based stress reduction vs escitalopram for anxiety disorders. JAMA Psychiatry. 2023;80(1):13-21.
5. Stubbs B, et al. An examination of the anxiolytic effects of exercise for anxiety and stress-related disorders. Psychiatry Res. 2017;249:102-108.
6. LeDoux JE. Anxious: Using the Brain to Understand and Treat Fear and Anxiety. Viking, 2015.
7. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe. Eur Neuropsychopharmacol. 2005;15(4):357-376.
8. Bandelow B, et al. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2022;24(1):37-53.